PE20160125A1 - Pirazolpiridinas sustituidas - Google Patents

Pirazolpiridinas sustituidas

Info

Publication number
PE20160125A1
PE20160125A1 PE2016000029A PE2016000029A PE20160125A1 PE 20160125 A1 PE20160125 A1 PE 20160125A1 PE 2016000029 A PE2016000029 A PE 2016000029A PE 2016000029 A PE2016000029 A PE 2016000029A PE 20160125 A1 PE20160125 A1 PE 20160125A1
Authority
PE
Peru
Prior art keywords
compounds
hydrogen
pyrazolo
pyrrolo
pyrimidin
Prior art date
Application number
PE2016000029A
Other languages
English (en)
Inventor
Keith Graham
Georg Kettschau
Ulrich Klar
Philip Lienau
Lars Wortmann
Florian Puehler
Anja Richter
Franziska Siegel
Detlev Sulzle
Kirstin Petersen
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51162789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160125(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of PE20160125A1 publication Critical patent/PE20160125A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos de pirazolpiridina sustituidas que inhiben la quinasa MKNK1 y/o quinasa MKNK2 de formula general I, metodos para preparar dichos compuestos, compuestos intermediarios utiles para preparar dichos compuestos, composiciones farmaceuticas y combinaciones que comprenden a dichos compuestos para el tratamiento de un trastorno hiperproliferativo y/o de angiogenesis. Donde: Q-V es un grupo seleccionado de C (R1a)-N, N-C(R1a); A representa un compuesto de formula (i), etc; * indica el punto de union de dichos grupos al resto de la molecula. R1a es hidrogeno, etc; R1b es hidrogeno, etc; R1c es hidrogeno, etc; R2a es hidrogeno, etc; R2b es hidrogeno, etc. Son compuestos preferidos: [N-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazolo[3,4-b]piridin-5-amina]; [N-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazolo[3,4-c]piridin-5-amina].
PE2016000029A 2013-07-08 2014-07-04 Pirazolpiridinas sustituidas PE20160125A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13175526 2013-07-08
EP13194902 2013-11-28
EP13195131 2013-11-29

Publications (1)

Publication Number Publication Date
PE20160125A1 true PE20160125A1 (es) 2016-03-17

Family

ID=51162789

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000029A PE20160125A1 (es) 2013-07-08 2014-07-04 Pirazolpiridinas sustituidas

Country Status (24)

Country Link
US (1) US20160159789A1 (es)
EP (1) EP3019505A1 (es)
JP (1) JP2016527216A (es)
KR (1) KR20160030239A (es)
CN (1) CN105531279A (es)
AP (1) AP2016009025A0 (es)
AU (1) AU2014289415A1 (es)
CA (1) CA2917380A1 (es)
CL (1) CL2016000038A1 (es)
CR (1) CR20160016A (es)
CU (1) CU20160003A7 (es)
DO (1) DOP2016000007A (es)
EA (1) EA201690183A1 (es)
HK (1) HK1223362A1 (es)
IL (1) IL243273A0 (es)
MX (1) MX2016000163A (es)
NI (1) NI201600006A (es)
PE (1) PE20160125A1 (es)
PH (1) PH12016500054A1 (es)
SG (1) SG11201510391VA (es)
TN (1) TN2016000005A1 (es)
UY (1) UY35651A (es)
WO (1) WO2015004024A1 (es)
ZA (1) ZA201600275B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201605867A (zh) * 2013-11-20 2016-02-16 拜耳製藥公司 噻吩并嘧啶
KR20180004740A (ko) * 2015-04-20 2018-01-12 이펙터 테라퓨틱스, 인크. 암 및 감염 치료에 사용하기 위한 면역 체크포인트 조절 인자의 억제제
GB201520500D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
SG11201901197PA (en) 2016-08-24 2019-03-28 Arqule Inc Amino-pyrrolopyrimidinone compounds and methods of use thereof
WO2018134335A1 (en) * 2017-01-20 2018-07-26 Bayer Pharma Aktiengesellschaft Substituted imidazopyridinpyrimidines
WO2021005183A1 (en) 2019-07-10 2021-01-14 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Inhibitor of map kinase interacting serine/threonine kinase 1 (mnk1) and map kinase interacting serine/threonine kinase 2 (mnk2), cancer therapy and therapeutic combinations
CN110483523B (zh) * 2019-08-27 2022-11-22 药雅科技(上海)有限公司 一种吡唑并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2530281C (en) * 2003-07-24 2013-02-12 Bayer Pharmaceuticals Corporation Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders
WO2007076161A2 (en) * 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
EP2265610B1 (en) * 2008-02-29 2012-12-12 Array Biopharma, Inc. Pyrazole [3, 4-b]pyridine raf inhibitors
CA2772316A1 (en) * 2009-08-28 2011-03-03 Array Biopharma Inc. 1h-pyrazolo [3,4-b] pyridine compounds for inhibiting raf kinase
AR080328A1 (es) * 2010-02-26 2012-03-28 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
WO2013071217A1 (en) * 2011-11-10 2013-05-16 OSI Pharmaceuticals, LLC Dihydropteridinones

Also Published As

Publication number Publication date
UY35651A (es) 2015-02-27
PH12016500054A1 (en) 2016-04-04
SG11201510391VA (en) 2016-01-28
CN105531279A (zh) 2016-04-27
AP2016009025A0 (en) 2016-02-29
EP3019505A1 (en) 2016-05-18
CU20160003A7 (es) 2017-02-02
CL2016000038A1 (es) 2016-07-29
IL243273A0 (en) 2016-02-29
CA2917380A1 (en) 2015-01-15
KR20160030239A (ko) 2016-03-16
US20160159789A1 (en) 2016-06-09
EA201690183A1 (ru) 2016-06-30
JP2016527216A (ja) 2016-09-08
TN2016000005A1 (en) 2017-07-05
DOP2016000007A (es) 2016-02-15
MX2016000163A (es) 2016-04-15
HK1223362A1 (zh) 2017-07-28
NI201600006A (es) 2016-02-12
CR20160016A (es) 2016-03-04
ZA201600275B (en) 2019-04-24
WO2015004024A1 (en) 2015-01-15
AU2014289415A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
UY38070A (es) Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer
DOP2019000030A (es) Inhibidores de cdk2/4/6
PE20170403A1 (es) COMPUESTOS DE IMIDAZO[4,5-c]QUINOLIN-2-ONA Y SU USO PARA TRATAR CANCER
CO2021006114A2 (es) Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer
ECSP12011855A (es) COMPUESTOS DE pIrrolo[2,3-d]pIrimidinA
UY34870A (es) Cristales de sal
PE20151776A1 (es) Compuestos de heteroarilo y sus usos
MX2015011311A (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y analogos del mismo como inhibidores de atotaxina.
UY39887A (es) (r)-(2-cloro-3-(trifluorometil)fenil)(1-(5-fluoropirimidin2-il)-4-metil-6,7-dihidro-1h-[1,2,3]triazolo-[4,5-c]piridin5(4h)-il)metanona como modulador del receptor p2x7
ECSP12011691A (es) Compuestos de urea que contienen heteroarilo 5,6-bicíclicos como inhibidores de quinasa
CR20150524A (es) Compuestos de heteroarilo y sus usos
MX370000B (es) Novedosas n-acil-(3-sustituidas)-(8-sustituidas)-5,6-dihidro-[1,2, 4]triazolo[4,3-a]piracinas como antagonistas selectivos del receptor de nk-3, composición farmacéutica y métodos para su uso en trastornos mediados por el receptor de nk-3.
EA201390199A1 (ru) 2-замещенные-8-алкил-7-оксо-7,8-дигидропиридо[2,3-d]пиримидин-6-карбонитрилы и их применение
EA201890061A2 (ru) Производные пиразоло[1,5-a]пиридина и способы их применения
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
MX2019003724A (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2018008131A (es) Forma cristalina del inhibidor de la btk quinasa y metodo de preparacion de la misma.
DOP2013000082A (es) Heteroarilos y sus usos
CO6440524A2 (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus.
EA201390644A1 (ru) ГИДРАТ ТАРТРАТА 1-{(2S)-2-АМИНО-4-[2,4-БИС-(ТРИФТОРМЕТИЛ)-5,8-ДИГИДРОПИРИДО[3,4-d]ПИРИМИДИН-7(6H)-ИЛ]-4-ОКСОБУТИЛ}-5,5-ДИФТОРПИПЕРИДИН-2-ОНА
PH12016501699A1 (en) 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one derivatives and their use as antibacterial agents
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
EA201690716A1 (ru) ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ
SV2017005368A (es) [1,2,4] triazolo [4,3-b] piridazinas para su uso en el tratamiento de enfermedades proliferativas

Legal Events

Date Code Title Description
FD Application declared void or lapsed